| Income Statement | 2025-06-30 | 2025-03-31 | ||
|---|---|---|---|---|
| Total revenues | 25 | 16 | ||
| Research and development | 1,174 | 1,080 | ||
| Production costs | 10 | 10 | ||
| General and administrative | 1,487 | 2,545 | ||
| Total costs and expenses | 2,671 | 3,635 | ||
| Operating loss | -2,646 | -3,619 | ||
| Interest and other income | 10 | 11 | ||
| Interest expense and other finance costs | 149 | 124 | ||
| (loss) on warrant issuance | 0 | - | ||
| Gain (loss) on investments | -9 | 27 | ||
| Net loss | -2,794 | -3,705 | ||
| Basic loss per share | -3.68 | -0.05 | ||
| Diluted loss per share | -3.68 | -0.05 | ||
| Weighted average shares outstanding basic | 759,289 | 70,329,869 | ||
| Weighted average shares outstanding diluted | 759,289 | 70,329,869 | ||
AIM ImmunoTech Inc. (AIMI)
AIM ImmunoTech Inc. (AIMI)